<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    7636666
   </pmid>
   <datecreated>
    <year>
     1995
    </year>
    <month>
     09
    </month>
    <day>
     11
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1995
    </year>
    <month>
     09
    </month>
    <day>
     11
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     14
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0022-3476
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       127
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        1995
       </year>
       <month>
        Aug
       </month>
      </pubdate>
     </journalissue>
     <title>
      The Journal of pediatrics
     </title>
     <isoabbreviation>
      J. Pediatr.
     </isoabbreviation>
    </journal>
    <articletitle>
     Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group.
    </articletitle>
    <pagination>
     <medlinepgn>
      322-8
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To compare the efficacy, safety, and tolerance of fluconazole suspension versus nystatin in the treatment of oropharyngeal thrush in immunocompromised children.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Multicenter, randomized, observer-masked trial.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Thirty-two centers participated, including hospitals and ambulatory care clinics.
     </abstracttext>
     <abstracttext label="PATIENTS" nlmcategory="METHODS">
      We enrolled 182 immunocompromised infants and children, ages 5 months to 14 years, with signs of oral thrush and presence of yeasts on potassium hydroxide- or gram-stained preparations. Subjects were randomly assigned to receive a single daily dose of fluconazole suspension, 2 to 3 mg/kg per day, or nystatin, 400,000 units four times daily for 14 days; 159 patients, who had culture confirmation of thrush and received at least 7 days of study drug, were evaluated for efficacy; all patients were evaluated for safety.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Clinical cure was demonstrated in 91% of the subjects in the fluconazole group and 51% of the subjects in the nystatin group (p &lt; 0.001), and eradication of the organism cultured at entry occurred in 76% and 11% (p &lt; 0.001), respectively. Gastrointestinal conditions developed in six patients who received fluconazole and in three who received nystatin; two fluconazole recipients were subsequently withdrawn from the study. Laboratory abnormalities occurred with equal frequency in both groups. Clinical relapse rates were similar in both groups at 2 weeks (18% and 24% for fluconazole and nystatin, respectively) and 1 month (28% and 27%, respectively) after the completion of study drug.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Fluconazole suspension is more effective than nystatin in the treatment of thrush in immunocompromised children. Both regimens were well tolerated.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Flynn
      </lastname>
      <forename>
       P M
      </forename>
      <initials>
       PM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cunningham
      </lastname>
      <forename>
       C K
      </forename>
      <initials>
       CK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kerkering
      </lastname>
      <forename>
       T
      </forename>
      <initials>
       T
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       San Jorge
      </lastname>
      <forename>
       A R
      </forename>
      <initials>
       AR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Peters
      </lastname>
      <forename>
       V B
      </forename>
      <initials>
       VB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Pitel
      </lastname>
      <forename>
       P A
      </forename>
      <initials>
       PA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Harris
      </lastname>
      <forename>
       J
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Gilbert
      </lastname>
      <forename>
       G
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Castagnaro
      </lastname>
      <forename>
       L
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Robinson
      </lastname>
      <forename>
       P
      </forename>
      <initials>
       P
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <grantlist completeyn="Y">
     <grant>
      <grantid>
       P30 CA 21765
      </grantid>
      <acronym>
       CA
      </acronym>
      <agency>
       NCI NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
    </grantlist>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
     <publicationtype>
      Research Support, U.S. Gov't, P.H.S.
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     J Pediatr
    </medlineta>
    <nlmuniqueid>
     0375410
    </nlmuniqueid>
    <issnlinking>
     0022-3476
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      1400-61-9
     </registrynumber>
     <nameofsubstance>
      Nystatin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      86386-73-4
     </registrynumber>
     <nameofsubstance>
      Fluconazole
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <citationsubset>
    X
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Oral
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Candidiasis, Oral
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child, Preschool
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Fluconazole
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      HIV Infections
     </descriptorname>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Immunocompromised Host
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Immunosuppression
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Infant
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Neoplasms
     </descriptorname>
     <qualifiername majortopicyn="N">
      immunology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Nystatin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Recurrence
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1995
     </year>
     <month>
      8
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1995
     </year>
     <month>
      8
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1995
     </year>
     <month>
      8
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     7636666
    </articleid>
    <articleid idtype="pii">
     S0022347695003933
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

